So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
So-Young International Inc.NASDAQ: SY
Accounts Receivables · Q4 FY2025 · quarter ended Dec 2025
Accounts receivables outflow grows to CN¥29.72M
Q4 FY2025 accounts receivables was CN¥29.72M, compared with CN¥0 a year earlier. Trailing-twelve-month accounts receivables was CN¥29.72M. Over 3 fiscal years it compounded at +29.9% a year.
Context
- Accounts receivables amounted to 2.0% of revenue in FY2025, down 2.2 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near CN¥29.72M or moves back toward the trailing-twelve-month quarterly average of CN¥7.43M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
CNY · from the cash flow
- Latest · FY2025
- 29.72M CNY
- Year-over-year change
- +148.3%
- 4-year CAGR
- +19.5%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.72M | +148.3% |
| FY2024 | 2024-12-31 | (61.48M) | -112.4% |
| FY2023 | 2023-12-31 | (28.95M) | -313.4% |
| FY2022 | 2022-12-31 | 13.56M | -7.0% |
| FY2021 | 2021-12-31 | 14.58M | — |
Accounts Receivables vs competitors
How SY compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Accounts receivables amounts to 2.0% of revenue for SY, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | CN¥29.72M CNY | — | +29.9% | 2.0% | |
| LTM Mar 2026 | $29.33M USD | -49.3% | — | 296.5% | |
| LTM Mar 2026 | $9.33M USD | +913.2% | — | 13.4% | |
| LTM Mar 2026 | $7.32M USD | -18.8% | +8.1% | 1.8% | |
| LTM Apr 2026 | $3.7M USD | -169.8% | — | 0.4% | |
| LTM Mar 2026 | $3.43M USD | -549.9% | — | 4.2% | |
| LTM Feb 2026 | $1.68M USD | +27.5% | -47.2% | 2.1% | |
| LTM Mar 2026 | $1.1M USD | -82.4% | — | 1.3% | |
| LTM Mar 2026 | $516.86K USD | +106.0% | -41.0% | 0.7% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding SY) | — | -34.0% | -41.0% | 1.9% | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (37.64M) | (66.11M) | 25.94M | (587.18M) | (246.91M) |
| Depreciation & Amortization | 30.08M | 47.09M | 46.09M | 45.92M | 57.21M |
| Deferred Income Tax | 1.65M | (24.8M) | (33.52M) | (16.17M) | (1.79M) |
| Stock-Based Compensation | 106.15M | 43.34M | 36.32M | 32.66M | 8.92M |
| Change in Working Capital | (164.54M) | (195M) | (122.45M) | (167.85M) | (26.11M) |
| Accounts Receivables | 14.58M | 13.56M | (28.95M) | (61.48M) | 29.72M |
| Inventory | 7.87M | (27.99M) | (2.12M) | (36.75M) | (115.98M) |
| Accounts Payables | (158.37M) | 0 | 0 | 0 | 0 |
| Other Working Capital | (28.61M) | (180.58M) | (91.37M) | (69.62M) | 60.14M |
| Other Non-Cash Items | 148.58M | 82.62M | 70.11M | 666.99M | 103.29M |
| Operating Cash Flow | 84.29M | (112.87M) | 22.5M | (25.63M) | (105.39M) |
| Capital Expenditures | (45.06M) | (15.71M) | (51.18M) | (62.55M) | (196.62M) |
| Acquisitions (Net) | (636.87M) | (97.49M) | 0 | 0 | 0 |
| Purchases of Investments | (2.02B) | (1.21B) | (2.27B) | (1.22B) | (872.29M) |
| Sales of Investments | 3.05B | 764.79M | 2.1B | 1.53B | 1.03B |
| Other Investing Activities | (8.37M) | (18.03M) | 17.16M | 10.85M | 500K |
| Investing Cash Flow | 339.82M | (572.21M) | (202.61M) | 257.04M | (42.81M) |
| Debt Repayment | 0 | 0 | 29.83M | 40M | (30M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 79K |
| Common Stock Repurchased | (217.71M) | (15.12M) | (125.62M) | (18.24M) | (15.25M) |
| Dividends Paid | 0 | 0 | 0 | (43.57M) | (19.03M) |
| Other Financing Activities | 969K | 1.54M | (4.22M) | 298K | 500K |
| Financing Cash Flow | (216.74M) | (13.59M) | (100.02M) | (21.51M) | (63.7M) |
| Effect of Forex Changes | (9.24M) | 55.86M | 11.87M | 3.34M | (1.48M) |
| Net Change in Cash | 198.12M | (642.81M) | (268.26M) | 213.23M | (213.38M) |
| Free Cash Flow | 39.23M | (128.58M) | (28.68M) | (88.18M) | (302.01M) |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.